Original Article
Tanshindiol C inhibits proliferation and induces apoptosis in non-small cell lung cancer by modulating miR-491-3p expression

Dan Gu*, Hui-Wen Weng*, Bi-Yu Xu

Department of Traditional Chinese Medicine, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China. *Equal contributors.

Received March 14, 2019; Accepted June 6, 2019; Epub August 15, 2019; Published August 30, 2019

Abstract: Background: Tanshindiol C (TanC) has been validated to repress proliferation in several cancer cell types. However, the underlying molecular mechanism of TanC on non-small cell lung cancer (NSCLC) cell proliferation and apoptosis is unclear. The aim of the present study was to explore whether microRNAs (miRNAs) and downstream target were involved in TanC-induced NSCLC cell death in vitro. Methods: miRNAs expression profiling was analyzed in A549 cells with or without TanC treatment using miRNAs microarray. Cell viability and apoptosis were detected using CCK8 and Annexin V-fluorescein isothiocyanate/propidium iodide (Annexinv-FITC) double staining, respectively. Bioinformatics algorithms and luciferase reporter assay were performed to verify c-MYC as a direct target of miR-491-3p. Results: TanC showed an anti-proliferative and pro-apoptotic activity in A549 and H358 cells. We also found that an increase in miR-491-3p and a decrease in c-MYC expression levels were observed in TanC-stimulated A549 and H358 cells. c-MYC was a direct target of miR-491-3p, and overexpression of miR-491-3p repressed c-MYC protein expression by directly binding with the 3’-UTR of c-MYC. miR-491-3p mimics induced growth inhibition and apoptosis were abolished by the overexpression of c-MYC in A549 and H358 cells. Conclusion: TanC had an effective ability to inhibit proliferation and induce apoptosis in NSCLC cells, and the underlying mechanism was mediated, at least partially, by regulating miR-491-3p/c-MYC signaling pathway.

Keywords: Non-small cell lung cancer, tanshindiol C, miR-491-3p, c-MYC, apoptosis

Introduction

Lung cancer is one of the most common malignant tumors and the leading cause of cancer-related death worldwide, accounting for approximately 13% of total cancer cases [1]. Cancer statistics in China estimates that 733,300 cases is newly diagnosed and 610,200 deaths occur in 2015 [2]. In addition, about 85% of lung cancer cases are diagnosed with non-small cell lung cancer (NSCLC), with a 5-year survival rate less than 20% [3]. Although important advancements of pharmacotherapy have been achieved in the treatment of NSCLC, the overall survival rates for NSCLC remain low, particularly in advanced and metastatic disease [4]. Therefore, continued research of new treatment strategies is significant for improving outcomes in NSCLC patients.

Tanshindiol C (TanC) is the major active ingredient of Salvia miltiorrhiza Bge, which is a traditional Chinese medicine for the prevention and treatment of several diseases, including atherosclerosis [5], type 2 diabetes mellitus [6] and immune disorders [7]. Recently, several active ingredients, such as tanshinone I [8], tanshinone IIA [9, 10], cryptotanshinone [11, 12] salvianolic acid A and B [13, 14], of Salvia miltiorrhiza Bge have been validated to exhibit an antineoplastic activity in various types of human cancer. However, the roles and underlying molecular mechanisms of TanC on proliferation and apoptosis of human NSCLC cells are still unclear.

MicroRNAs (miRNAs/miRs) as a class of non-coding RNAs (approximately 22 nucleotides) perform a primarily function to repress tran-
TanC induces NSCLC cells death

scription or translation of target genes by binding with the 3'-untranslated region (3'-UTR) of target messenger RNA (mRNA), which results in mRNA cleavage and degradation or translational repression [15]. Previous studies have been identified that numerous miRNAs are reported in a variety of physiological and pathological processes, including tumorigenesis [16, 17]. Accumulating evidence reveals that deregulation of miRNAs contributes to the initiation and progression of NSCLC [18, 19]. Our present study aimed to investigate miRNAs expression profiling in TanC-treated NSCLC cells using miRNAs microarray assays, and the results demonstrated that miR-491-3p was significantly up-regulated in TanC-treated NSCLC cells. Subsequently, we validated the expression of miR-491-3p in NSCLC cells using RT-qPCR analysis. Furthermore, in vitro experiments were performed to detect the roles of miR-491-3p on proliferation and apoptosis via transfection with miR-491-3p mimics or inhibitors into NSCLC cells.

Materials and methods

Cell culture

Human normal 16HBE cells (Cell Bank of China Academy of Sciences, Shanghai, China) and four kinds of NSCLC cells (ATCC, American Type Culture Collection, Manassas, VA, USA), A549, H358, SK-MES-1 and H1299, were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Invitrogen, Carlsbad, CA, USA) with 10% fetal bovine serum (Thermo Scientific HyClone, Beijing, China), 100 U/ml penicillin and 100 mg/ml streptomycin in a humidified incubator (Thermo Fisher Scientific, Inc., Waltham, MA, USA), 5% CO₂, 95% air atmosphere.

CCK8 assay

NSCLC cells (1×10⁴) were seeded in the 96-well plate and cultured with CCK8 solution (10 μL, Beyotime Institute of Biotechnology, Haimen, China). A spectrophotometer (Thermo Scientific HyClone, Beijing, China), 100 U/ml penicillin and 100 mg/ml streptomycin in a humidified incubator (Thermo Fisher Scientific, Inc., Waltham, MA, USA), 5% CO₂, 95% air atmosphere.

miRNAs microarray analysis

Differentially expressed miRNAs in A549 cells with or without TanC treatment were analyzed using the SurePrint G3 Human miRNA Microarray (8x60K, Agilent Technologies, Santa Clara, CA, USA) according to previously described method [20].

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)

Total RNA was isolated using RNAiso (Takara, Dalian, China). TaqMan® RT kit (Applied Biosystems; Thermo Fisher Scientific, Inc.) and TaqMan® MicroRNA assay (Applied Biosystems; Thermo Fisher Scientific, Inc.) were used to measure the expression levels of miRNAs using Applied Biosystems 7300 Real-Time PCR System (Thermo Fisher Scientific, Inc.) and normalized to the internal control U6. miRNAs expression levels were calculated using the 2^ΔΔCq method [20]. In addition, TaqMan Universal PCR Master Mix (Thermo Fisher Scientific, Inc.) was used to measure the expression levels of c-MYC using Applied Biosystems 7300 Real-Time PCR System. c-MYC mRNA expression levels were calculated using the 2^ΔΔCq method [21] and normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH). The primers were shown as follows: c-MYC: forward primer 5’-CC-TGGTGCCTCATGAGGAGAC-3’ and reverse primer 5’-CAGACTCTGACCTTTGTCCAGG-3’; GAPDH: forward primer 5’-TGCGCCAGGGTGCTAAG-3’ and reverse primer 5’-AGCCTAAAGGCGTATC-3’.

Annexinv-FITC double staining for apoptosis

Cell apoptosis was analyzed using Annexin V-FITC/PI double staining kit (Invitrogen, Carlsbad, Calif, USA). Flow cytometry (FACScan, BD Biosciences, San Jose, CA, USA) and CELL Quest 3.0 software (BD Biosciences) were used to calculate the apoptotic cell proportion in A549 and H358 cells.

miRNA and plasmid transfection

miR-control (miR-Con; 5’-CUUGUGGUAUGUC-CUGUAGU-3’), miR-491-3p mimics (5’-CUA-UCAAGAUCUUCCUCCAUGUGUAUGU-3’) and inhibitors (5’-UAAGGUGGAUCUUGCAUAGGUAUGU-3’) were synthesized by Guangzhou RiboBio Co., Ltd. (Guangzhou, China). A mammalian expression plasmid designed to specially express the full-length open reading frame of human c-MYC without 3'-UTR was purchased from GeneCopoeia, Inc. (Rockville, MD, USA). An empty plasmid served as the negative control. miR-Con, miR-491-3p mimics, inhibitors, vector-Con and vector-c-MYC were transfected into A549 and H358.
TanC induces NSCLC cells death

cells using Lipofectamine 2000 for 48 h at 37°C, according to the manufacturer's protocols.

Luciferase reporter assay

The wild-type (WT) and mutant-type (MUT) 3'-UTR of c-MYC were inserted into the multiple cloning sites of the luciferase expressing pMIR-REPORT vector (Ambion; Thermo Fisher Scientific, Inc.), which were co-transfected with miR-Con, miR-491-3p mimics or inhibitors into A549 and H358 cells. The luciferase activity was measured using a luciferase reporter assay kit (Promega, Madison, WI, USA). Protein bands were visualized using chemiluminescence (Thermo Fisher Scientific, Inc.). Signals were analyzed with Quantity One® software version 4.5 (Bio Rad Laboratories, Inc., Hercules, CA, USA). β-actin (cat.#: sc-130301; dilution: 1:2,000; Santa Cruz Biotechnology, Santa Cruz, CA, USA) signals were used to correct for unequal loading.

Statistical analysis

All data were showed as mean ± standard error of mean. PRISM version 7.0 (GraphPad Software, Inc., La Jolla, CA, USA) was used to perform the statistical analysis. Inter-group differences were analyzed by one-way analysis of variance, followed by a post hoc Tukey test for multiple comparisons. P < 0.05 was considered as statistical significance.

Results

TanC exhibited the ability to induce growth inhibition in NSCLC cells

To explore the antineoplastic activity of TanC in vitro, we investigated the cytotoxicity of TanC on human normal 16HBE cells, and the results demonstrated that TanC treatment had no obvious influence on cell viability when cultured for 48 h (B). CCK8 assays were used to detect the cell viability of A549 (C), H358 (D), SK-MES-1 (E) and H1299 (F) cells with or without TanC treatment for 48 h. *P < 0.05, **P < 0.01, ***P < 0.001 compared with the control group.
TanC induces NSCLC cells death

Data indicated that TanC had the ability to prevent NSCLC cell proliferation in vitro.

miRNAs expression profiling in TanC-treated A549 cells

To determine the molecular mechanism underlying TanC-induced growth inhibition in NSCLC cells, we utilized miRNAs microarray to analyze miRNAs expression profiling in TanC-treated A549 cells. Based on \(|\text{Log2 fold change}| \geq 2\) and FDR ≤ 0.001, 22 miRNAs were significantly differentially expressed in TanC-stimulated A549 cells compared with that in the control group. Among these miRNAs, 4 miRNA were down-regulated and 18 miRNAs were up-regulated in TanC-stimulated A549 cells (Figure 2A). In addition, we observed that the expression levels of miR-491-3p were higher than other miRNAs in response to TanC stimulation. Therefore, we focused on miR-491-3p in our further study. To validate the regulation function of TanC on miR-491-3p expression, RT-qPCR was performed to measure miR-491-3p...
TanC induces NSCLC cells death

expression in TanC-stimulated A549 and H358 cells, and an up-regulation of miR-491-3p expression was observed in A549 and H358 cells after exposure to TanC (Figure 2B and 2C). Interestingly, transfection with miR-491-3p inhibitors into A549 and H358 cells blocked TanC-induced up-regulation of miR-491-3p expression (Figure 2B and 2C). Taken together, these findings suggested that miR-491-3p, as a post-transcriptional regulator, might be involved in TanC-induced NSCLC cell growth inhibition.

Furthermore, we examined cell apoptosis in TanC-treated NSCLC cell. AnnexinV-FITC double staining assays revealed that the apoptotic cell proportion was markedly increased in TanC-treated A549 and H358 cells as compared to the control group. Moreover, miR-491-3p inhibitors had been shown to attenuate the effects of TanC on cell apoptosis (Figure 3A and 3B). These data indicated that TanC-induced NSCLC cell growth inhibition and apoptosis might be associated with the up-regulation of miR-491-3p expression in A549 and H358 cells.

miR-491-3p negatively regulated c-MYC by directly binding to its 3'UTR

To further investigate the potential target of miR-491-3p, bioinformatics algorithm was executed by Targetscan (www.targetscan.org) to predict the downstream target of miR-491-3p. We found that the 3'UTR of c-MYC could bind to miR-491-3p with the high score, and the analogous complementary pairing domain (Figure 4A). Thus, a luciferase reporter assay was conducted to confirm whether c-MYC was a direct target of miR-491-3p. The luciferase activity was significantly reduced in A549 and H358 cells co-transfected with WT 3'UTR of c-MYC and miR-491-3p mimics, while the luciferase activity was significantly increased in A549 and H358 cells co-transfected with WT 3'UTR of c-MYC and miR-491-3p inhibitors (Figure 4B). However, the luciferase activity was not influenced by miR-491-3p mimics or inhibitors in A549 and H358 cells containing Mut 3'UTR of c-MYC (Figure 4B). Western blotting experiments showed that the negative regulatory effect of miR-491-3p mimics (Figure 4C) and TanC (Figure 4D) on c-MYC protein expression was observed in A549 and H358 cells.

Overexpressed c-MYC rescued the miR-491-3p-mediated effects

Base on the above results, we found that miR-491-3p and c-MYC might play the reciprocal roles in the progression of NSCLC. We also found that the expression of miR-491-3p was dramatically decreased, and c-MYC was markedly increased in NSCLC cell lines compared with human normal 16HBE cells (Figure 5A). To
TanC induces NSCLC cells death

**Discussion**

Recently, several studies point to expand multiple pharmacological functions and molecular mechanisms of TanC for human disease therapeutic applications [23, 24]. For instance, TanC is proposed as a potential anti-atherosclerotic agent via activating anti-oxidant peroxiredoxin 1/adenosine triphosphate-binding cassette transporter A1 signaling pathway, which contributes to inhibition of oxidized low-density lipoprotein induced macrophage foam cell formation [24]. In addition, TanC can serve as methyltransferase inhibitor and possesses an anticancer activity in various tumor cell lines, including lymphoma, prostate cancer, glioma and lung adenocarcinoma, through the inhibition of EZH2 activity [23].

In the present study, we further explored the antineoplastic activity and the underlying molecular mechanisms of TanC in NSCLC. Our findings revealed that TanC treatment led to a decrease in growth rate and an increase in apoptotic proportion of A549 and H358 cells, and the underlying mechanism was mediated,

---

**Figure 4.** miR-491-3p negatively regulated c-MYC by directly binding to its 3’-UTR. Targetscan (A) and luciferase reporter assay (B) was conducted to confirm whether c-MYC was a direct target of miR-491-3p. After transfection with miR-Con, miR-491-3p mimics or inhibitors into A549 and H358 cells for 48 h, the protein expression levels of c-MYC were measured using western blotting (C). A549 and H358 cells exposure to TanC (10 μM) for 48 h, the protein expression levels of c-MYC were measured using western blotting (D). *P < 0.05.
TanC induces NSCLC cells death

at least partially, by regulating miR-491-3p/c-MYC signaling pathway. Woo et al indicated that TanC represses growth of A549 cells with half maximal growth-inhibitory concentration of 4.2 ± 1.1 μM [23]. Consistent with this conclusion, our results showed that TanC significantly suppressed A549 cell proliferation when the concentration of TanC was more than 1 μM. Moreover, Woo et al also revealed that TanC can induce necrotic and apoptotic cell death in Pfeiffer cells [23].

On the other hand, miRNA microarray and RT-qPCR validated that TanC increased miR-491-3p expression in A549 and H358 cells. miR-491-3p, as a mature miRNA, is produced by miR-491 [25]. The biological function studies exhibited that miR-491-3p has been shown to inhibit proliferation, induce apoptosis and modulate chemo-sensitivity in different cancer types [25-27]. After transfection with miR-491-3p mimics into A549 and H358 cells, cell viability was found to be significantly reduced, and cell apoptotic rate was markedly elevated compared with the control group. These data suggested that miR-491-3p could function as a tumor suppressor in the tumorigenesis of NSCLC. This observation sparked our interest to investigate whether miR-491-3p mediated downstream target gene participates in these processes.

Notably, we found that c-MYC was a direct target of miR-491-3p, and overexpression of miR-491-3p repressed c-MYC protein expression by directly binding with the 3'-UTR of c-MYC. The transcription factor c-MYC, as an oncogene, has been reported to be associated with the initiation and progression of cancers [28] and is frequently found to be activated in various animal and human tumors [29, 30]. Although c-MYC has the ability to induce cell proliferation, pro-apoptotic function of c-MYC is discovered in cancer cells with high c-MYC levels, which may be associated with better treatment in response to anti-mitotic cancer therapeutics [31, 32]. These findings indicate that c-MYC may possess a peculiar dual role in the carcinogenesis. Miao et al shows that c-MYC mRNA and protein expression levels are higher in

Figure 5. Overexpressed c-MYC rescued the miR-491-3p-mediated effects. The mRNA levels of miR-491-3p and c-MYC were measured using RT-qPCR (A). After co-transfection with c-MYC overexpressed plasmids and miR-491-3p mimics into A549 and H358 cells, cell viability (B) and apoptosis (C and D) were detected using CCK8 and Annexin-FITC double staining, respectively. *P < 0.05.
TanC induces NSCLC cells death

NSCLC tissues and cell lines than those in the corresponding group [33]. Kysan et al demonstrated that an increase in c-MYC expression level is able to stimulate cell proliferation and promote resistance to pharmacologically induced apoptosis in NSCLC cells [34]. In our study, c-MYC was increased in A549 and H358 cells, and overexpression of c-MYC reversed the effect of miR-491-3p on NSCLC cell lines.

In conclusion, our study had identified that TanC possessed an effective ability to inhibit proliferation and induce apoptosis in NSCLC cells. More importantly, study on molecular mechanism reveals that miR-491-3p/c-MYC signaling pathway might be a novel therapeutic target of TanC for hindering the progression of NSCLC.

Disclosure of conflict of interest

None.

Address correspondence to: Dr. Bi-Yu Xu, Department of Traditional Chinese Medicine, The First Affiliated Hospital of Sun Yat-sen University, No. 58 Second Zhongshan Road, Guangzhou 510080, China. Tel: (+86)020-87755766-8387; Fax: (+86) 020-87755766-8387; E-mail: xubiyu@mail.sysu.edu.cn

References

TanC induces NSCLC cells death

UPR and ERAD to promote metastatic potential of NSCLC. Nat Commun 2018; 9: 5110.


